Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.72 |
| ▸ | CDK4 | P11802 | 8/20 | 0.72 |
| ▸ | CDK1 | P06493 | 3/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CCND1 | P24385 | 1/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.53 |
| ▸ | CCND3 | P30281 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | CDK7 | P50613 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | CCNH | P51946 | 1/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6595783 | 0.88 | CDK2 (0.77) | CDK2CDK4CDK1CCNT1CCNB1 | |
| SCHEMBL6597003 | 0.88 | CDK2 (0.69) | CDK2CDK4CDK1CCNT1CCNB1 | |
| SCHEMBL27514575 | 0.87 | CDK2 (0.72) | CDK2CDK4CDK1CCNT1CCNB1 | |
| SCHEMBL6595834 | 0.86 | CDK2 (0.81) | CDK2CDK4CDK1CCNT1CCNB1 | |
| SCHEMBL6596936 | 0.86 | CDK2 (0.81) | CDK2CDK4CDK1CCNT1CCNB1 | |
| SCHEMBL4024274 | 0.85 | CDK2 (0.62) | CDK2CDK4CDK1CCNT1CCNB1 | |
| SCHEMBL6106140 | 0.85 | CDK2 (0.78) | CDK2CDK4CDK1CCNT1CCNB1 | |
| SCHEMBL6596363 | 0.85 | CDK2 (0.75) | CDK2CDK4CDK1CCNT1CCNB1 | |
| SCHEMBL6596658 | 0.85 | CDK2 (0.72) | CDK2CDK4CDK1CCNT1CCNB1 | |
| SCHEMBL6104547 | 0.85 | CDK2 (0.78) | CDK2CDK4CDK1CCNT1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004033-A1 | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | ASTRAZENECA AB | 2006-01-05 | — | — | US | claimed |
| US-6969714-B2 | Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | claimed |
| EP-1351958-B1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2004-06-16 | — | — | EP | claimed |
| WO-2002020512-A9 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | WO | claimed |
| US-20040014776-A1 | Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | US | claimed |
| EP-1351958-A1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002020512-A1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | claimed |
| EP-1351958-B1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2004-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004033-A1 | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | MKI67, CCNI, CCNT1 | CDK2 13/4885CDK4 27/4885CDK1 28/4885 |
| US-20040014776-A1 | Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration | CCNI, TYMP, MKI67 | CDK2 11/4885CDK4 27/4885CDK1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.